Highly Potent Drugs

May 16, 2016
By Pharmaceutical Technology Editors
Combining powder micro-dosing services with the Xcelodose technology, Capsugel offers capabilities in both North America and Europe.
May 04, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
The production of antibody-drug conjugates requires biopharmaceutical and chemical manufacturing, and conjugation capabilities.
May 02, 2016
Pharmaceutical Technology
Safe handling of HPAPIs requires determining exposure potential and selecting appropriate containment strategies.
Apr 22, 2016
Highly potent or cytotoxic drugs require special handling
Apr 02, 2016
Pharmaceutical Technology
Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems.
Mar 24, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Collaboration will provide for unified development and manufacture of antibody drug conjugates.
Mar 01, 2016
Pharmaceutical Technology Europe
The author lists five key areas to consider when selecting a CDMO to develop highly potent formulations.
Feb 18, 2016
Manufacturing of antibody drug conjugates requires high-containment solutions, such as high-performance aseptic isolators.
Jan 01, 2016
Pharmaceutical Technology
Liquid formulations in hard-shell capsules or softgels are becoming a popular option for HPAPIs because of advantages such as improved safety and lower risk of potential exposure and product cross contamination.
Nov 05, 2015
Biotech boom, niche markets, smaller batch sizes and high potency manufacturing are among the key trends shaping the pharmaceutical industry of the 21st century, according to Christian Treitel from Bosch Packaging Technology.
lorem ipsum